You are here: Industry Insights > Novartis

News List

Novartis divests anti-infectives brands to Samara Capital expressbpd
October 09, 2017
The portfolio of brands acquired focus on anti-infectives largely catering to the women’s health and gynaecology segment
Novartis, UC Berkeley join forces for ‘undruggable’ targets fiercebiotech
September 29, 2017
Novartis and UC Berkeley have formed a new pact aimed at unlocking difficult drug targets and boosting development of new meds in infectious diseases and cancer.
Novartis and UC Berkeley collaborate to tackle 'undruggable' disease targets worldpharmanews
September 29, 2017
Novartis has joined forces with researchers from the University of California, Berkeley, to develop new technologies for the discovery of next-generation therapeutics
Novartis and The Max Foundation to provide cancer access programme in lower-income countries pharmaceufical-technology
September 27, 2017
The two entities have long been collaborating on providing access to care for patients in lower-income countries through the Glivec International Patient Assistance Program (GIPAP).
Novartis and The Max Foundation transform pioneering cancer access program for people in lower-incom worldpharmanews
September 25, 2017
Novartis announced a new collaboration with The Max Foundation to support continued access to treatment at no cost for nearly 34,000 current patients with chronic myeloid leukemia (CML
Novartis scores EU approval in acute myeloid leukaemia and advanced systemic mastocytosis pharmafile
September 21, 2017
Novartis has announced that its targeted therapy Rydapt (midostaurin) has received EU approval in the two rare cancer indications
Novartis' Xolair shows strong retreatment efficacy at Phase 3 in chronic spontaneous urticaria pharmafile
September 19, 2017
Novartis has released new data demonstrating the efficacy of Xolair (omalizumab) in the treatment of chronic spontaneous urticaria (CSU), a severe condition which causes persistent hives and painful deep swelling of the skin.
Novartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy worldpharmanews
September 18, 2017
Novartis has announced, first of its kind Phase III data showing Cosentyx® (secukinumab) delivered high and long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis at 5 years[1]
Novartis' Cosentyx proves long-term efficacy in psoriasis skin clearance pharmafile
September 14, 2017
At the European Academy of Dermatology and Venereology Congress in Geneva, Switzerland, Novartis unveiled new Phase 3 data for Cosentyx evidencing its long term skin clearance benefits and safety profile in the treatment of psoriasis
FDA accepts license application for Novartis' rituximab biosimilar pharmafile
September 13, 2017
FDA has accepted its Biologics License Application (BLA) for a proposed biosimilar version of Roche and Genentech’s Rituxan (rituximab)

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page